Home / Market News / Hepion Pharmaceuticals’ stock rockets after upbeat results of preclinical study of liver cirrhosis treatment

Hepion Pharmaceuticals’ stock rockets after upbeat results of preclinical study of liver cirrhosis treatment

Shares of Hepion Pharmaceuticals Inc. rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 liver cirrhosis treatment. Trading volume topped 836,000 shares, already more than half the full-day average of about 1.5 million shares. The company said late Wednesday that CRV431 prevented the development of liver cirrhosis in a “highly aggressive” model of liver disease. “The results align with previous findings in other experimental models and highlight the tremendous potential of CRV431 as a treatment for liver diseases, including NASH, where progression to cirrhosis is a primary medical concern,” said Chief Executive Robert Foster. The stock had plunged 88% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF had climbed 18% and the S&P 500 had advanced 24%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Read Full Story